Medi-Weightloss Review: What Its GLP-1 Program Documents—and What It Does Not Prove

A clinic can document regular appointments, medical testing and access to prescription drugs without demonstrating how much weight its own patients lose or how consistently its locations deliver care. That distinction matters when reading Medi-Weightloss’s advertising. The network describes a physician-led, primarily in-person program with nutritional support, repeated monitoring and medication options that include branded GLP-1 treatments and compounded semaglutide and tirzepatide. Those are meaningful service descriptions, but they are not the same as independently established treatment outcomes.

This review examines public documentation consulted October 19, 2026, separating advertised services, commercial terms and clinical evidence. The most useful question is not simply whether Medi-Weightloss offers GLP-1 medications—it explicitly says it does—but what a particular clinic will provide, prescribe and charge. Its free assessment differs from its $199 self-pay New Patient Visit, medication costs are separate, and several important arrangements require local confirmation. No clinic credentials, pharmacy licenses or patient outcomes were independently verified for this review.

At a glance

Care model: Medi-Weightloss describes physician-led, primarily in-person care, with weekly visits during Acute and Short-Term Maintenance phases and monthly visits in Wellness.
Sources: [10]
Initial self-pay charge: The $199 New Patient Visit includes a medical assessment, lab work and GLP-1 eligibility review; the earlier assessment is advertised as free.
Sources: [12] [10]
Medication pricing: Medication is separate from program fees. Compounded semaglutide starts at $99 for the first month and compounded tirzepatide at $199 for the first month; later prices are not established.
Sources: [12]
Prescription options: The network lists Wegovy, Zepbound, Saxenda, Contrave, phentermine, phendimetrazine and compounded semaglutide and tirzepatide; local availability and eligibility require provider confirmation.
Sources: [6]
Compounded-product distinction: Medi-Weightloss discloses that compounded products are not FDA approved or evaluated by FDA for safety, effectiveness or quality.
Sources: [11]

A documented clinic network, not a single verified care experience

Medi-Weightloss presents its program as physician-led, with patients meeting licensed medical providers in person. That wording does not establish that every appointment is with a physician. The program page describes more than 130 clinics, while the locator advertises 139 locations and offers ZIP-code searching. These statements establish the network’s advertised scale, not that every treatment, practitioner type or appointment format is available at every location. A nearby listing is a starting point for confirmation, not proof of access.

The corporate structure also matters when interpreting national claims. Website terms say businesses and area managers operate as separate legal entities under franchise or fractional-franchise agreements and are not the central company’s agents or employees. A reader should therefore establish the local clinical entity, responsible professionals and payment recipient rather than assuming the entire network is one treating organization. The consulted documentation does not identify those parties for every clinic.

The locator itself contains duplicated or conflicting entries, including different addresses for De Pere/Green Bay and repeated Los Gatos blocks. Confirm the address directly before traveling. Online booking is described at the local-clinic level, and many locations advertise telehealth support between visits, rather than a uniformly remote service. These are examples of what public provider documents can establish: advertised access and organizational structure, but not independently verified local performance.

Sources: [10] [4] [6]

What the assessment and first medical visit actually establish

Enrollment begins with an advertised free assessment, followed by a New Patient Visit. These are distinct steps, not interchangeable descriptions of a free medical workup. Medi-Weightloss says the treatment plan considers metabolic rate, health profile and personal preferences. Its typical initial workup includes medical and health history, a blood panel, an EKG and body-composition analysis. Recent primary-care examination results, blood work or an EKG may be accepted after the patient signs a release permitting access.

For the first appointment, the network requests photo identification, an insurance card when applicable, a current medication and supplement list, and recent laboratory or physical-examination results. Booking ahead is recommended because the visit includes assessment, laboratory work and GLP-1 eligibility review. Some locations may accommodate same-day appointments; others book farther ahead. The documentation does not establish a standard appointment length, turnaround for laboratory results or deadline for a prescribing decision.

The program describes itself as potentially helpful for people with BMI of 25 or higher, people considering weight-management medication and people with certain metabolic conditions. That is program-level marketing, not sufficient eligibility for a particular drug. The standard program is for adults, while a separate adolescent program serves ages 12–18. Separately, the website terms prohibit access to the sites or use of the services by anyone under 18 or not legally an adult where they live; families should clarify how a parent or guardian arranges adolescent care. Pregnancy or breastfeeding participation is described as case-by-case, coordinated with an OB/GYN or primary-care doctor—not blanket permission for medication use.

Sources: [10] [6] [9] [4]

Follow-up is described more clearly than response times

The network specifies weekly clinic visits during its Acute Weight Loss and Short-Term Maintenance phases, then monthly visits during Wellness. Typical follow-ups include body-composition measurements, weight and other measurements, nutrition and habit review, medication side-effect monitoring when applicable, and plan updates. This is a more concrete description than an unspecified promise of ongoing support. It still does not establish how consistently each clinic follows the schedule or how quickly patients can obtain help between appointments.

Support also includes nutrition and fitness education, behavioral coaching around emotional eating, stress and sleep, and access to a patient membership website. The eating plan is described as grocery-store food supplemented by Medi-Weightloss Signature Products, with optional Signature Menus for meal planning. It is not presented as an exclusively prepackaged-food program. Readers should distinguish the documented availability of these resources from evidence that any particular resource independently improves outcomes.

NIDDK describes medication follow-up as a question of tolerance and response, not simply payment continuation. That makes the network’s monitoring description relevant, while leaving practical questions unanswered: Who responds to medication concerns between visits, through which channel, and within what timeframe? The public materials do not provide a uniform response standard. Our guide to clinical follow-up beyond renewal notices explains why appointment frequency and access to timely clinical advice are related but different features.

Sources: [6] [10] [2]

Medication names do not settle the product-evidence question

The medication list includes Wegovy, identified as semaglutide; Zepbound, identified as tirzepatide; and Saxenda, identified as liraglutide. It also lists Contrave and the oral appetite suppressants phentermine and phendimetrazine, alongside compounded semaglutide and compounded tirzepatide. These are not all the same medication category. The network says a provider confirms eligibility and specific availability at the New Patient Visit, and prescription medications require medical evaluation and approval rather than a questionnaire alone.

The documentation does not clearly establish every offered GLP-1 product’s route, presentation, supplied quantity or compounded formulation. Those omissions prevent a precise product-level comparison, even when ingredient names sound familiar. As explained in why formulation and route matter, an ingredient name alone does not connect an offering to all evidence involving that ingredient. The review therefore does not infer injectable delivery, a particular concentration or a branded product’s presentation for the compounded promotions.

Medi-Weightloss explicitly discloses that compounded drugs are not FDA approved or evaluated by FDA for safety, effectiveness or quality. FDA similarly explains that compounded preparations do not undergo its premarket review. Nonapproval alone does not prove clinical inequivalence, but neither does a familiar ingredient establish equivalence. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy. That distinction deserves a patient-specific explanation from the prescriber.

Sources: [6] [11] [10] [1]

Named pharmacies improve transparency, but leave delivery unresolved

For compounded options, Medi-Weightloss says its provider determines suitability and sources medication directly from a pharmacy it describes as licensed, without requiring the patient to find one. Its published partner list includes BPI Labs, Innovation Compounding, EverWell Pharmacy and Nova Specialty Pharmacy, with addresses in Florida, Georgia and Texas. It also names Absolute Pharmacy, Belmar Pharma Solutions, AnazaoHealth and Empower Pharmacy. These are provider-reported relationships, not independently verified licensing findings or proof that any one pharmacy serves a particular patient.

The list does not identify which pharmacy supplies each clinic, prescription or formulation. Nor does the documentation establish whether medication is picked up locally or delivered to the home, who pays shipping charges, how temperature control works, or when dispatch and arrival occur. Before purchasing, request the dispensing pharmacy’s identity, exact product description and fulfillment instructions. Sourcing a prescription through a named pharmacy is a documented process claim; it is not, by itself, evidence of clinical effectiveness.

For any injectable GLP-1 shipment, FDA explicitly advises not using a product that arrives warm or with insufficient refrigeration and contacting the provider or dispensing pharmacy. FDA also reports errors measuring or administering compounded medications, including some associated with hospitalization; unclear instructions should be resolved with the prescriber or pharmacist. These are general regulatory concerns, not a Medi-Weightloss-specific event rate. The distinction between approved medicines and compounded preparations should remain visible throughout prescribing and fulfillment.

Sources: [9] [1]

Published prices establish entry points, not a complete treatment bill

For self-pay patients, the $199 New Patient Visit includes medical assessment, laboratory work and GLP-1 eligibility review. It is followed by one-, three- or six-month program options whose prices depend on clinic and plan. Those durations do not, on their own, establish medication supply, a minimum commitment or mandatory advance payment. Medication is priced separately from the program. Consequently, neither the initial visit price nor a promotional medication price is a reliable stand-in for the full recurring bill.

The pricing page offers compounded semaglutide starting at $99 for the first month and compounded tirzepatide starting at $199 for the first month when discussing alternatives to uncovered branded GLP-1s. These are starting prices for an introductory month, not published ongoing rates. The materials do not establish the promotions’ complete formulation, route, presentation, quantity or all eligibility conditions. Ask for the precise product and subsequent charges in writing rather than assuming the first-month amount continues.

For insured visits, the provider says most patients pay $0–$50 per visit depending on coverage and deductible status. That is a commercial claim, not an individual benefit determination. Insurance acceptance for a consultation does not establish coverage for medication, and the patient remains responsible for copays, deductibles, coinsurance and noncovered services. The following distinctions are the clearest available basis for requesting a local estimate; they should not be added together as a universal package price.

What the published amounts do—and do not—cover
Item	Documented price or structure	Important boundary
Initial assessment	Advertised as free	Distinct from the paid New Patient Visit
Self-pay New Patient Visit	$199	Assessment, lab work and GLP-1 eligibility review
Compounded semaglutide	Starting at $99 for the first month	Separate from program fees; later price unspecified
Compounded tirzepatide	Starting at $199 for the first month	Separate from program fees; later price unspecified
Insured visits	Provider says most patients pay $0–$50 per visit	Depends on coverage and deductible; not guaranteed

Sources: [12] [2]

Included visits, optional extras and unresolved exit terms

The membership generally includes provider visits, body-composition analysis, nutrition plans and education, progress tracking and patient-website access. Follow-up visits are described as built into membership. That does not mean every service is included: medications, Signature Supplements, specialized treatments and repeat laboratory work may add charges. Initial laboratory work belongs to the New Patient Visit price. A useful written estimate should separate the core membership from these extras and explain how insured visit charges interact with the chosen arrangement.

Medi-Weightloss says it is not contract-based and does not require advance payment, while acknowledging that some locations offer value or loyalty plans requiring prepayment. Financing is advertised, with details available locally. The documentation does not clearly establish automatic renewal, cancellation deadlines, refunds or repayment of unused prepaid services. An optional prepaid offer should therefore be evaluated separately from ordinary participation. The existence of one-, three- and six-month options does not resolve those terms.

Additional offerings include IV therapy and vitamin or nutrient injections at many clinics. The injection page specifically says these injections are not for weight loss, despite describing general wellness benefits; those benefits remain provider claims here. The contact form permits a Spanish-language preference but does not establish Spanish-language clinical care everywhere. It also obtains consent for service and marketing texts and emails, notes possible message charges, and allows SMS opt-out by replying STOP.

Sources: [12] [8] [5] [7]

What research can support—and what remains unmeasured here

STEP 1 illustrates why medication evidence must remain product- and study-specific. This randomized trial involved 1,961 adults with obesity or overweight plus a weight-related condition, without diabetes. Over 68 weeks, mean weight change was −14.9% with studied subcutaneous semaglutide 2.4 mg weekly versus −2.4% with placebo; both groups received lifestyle intervention. Gastrointestinal events led to discontinuation in 4.5% versus 0.8%. Novo Nordisk funded the trial. The dose identifies the research arm, not instructions for readers or a Medi-Weightloss prescription.

Those findings do not measure Medi-Weightloss’s outcomes, validate its compounded preparations or predict an individual’s result. The consulted provider materials describe an organized service, but they do not establish a clinic-specific success rate, comparative safety rate or independently verified effectiveness of the complete program. Likewise, FDA approval attaches to a specific drug product, not to a clinic network or pharmacy. Advertised medical supervision and the existence of drug research answer different questions.

NIDDK emphasizes discussing benefits, side effects, health conditions, other medicines and costs with a clinician; medication accompanies healthy eating and physical activity rather than replacing them. Medi-Weightloss documents several compatible service components, including nutrition education and monitoring. What remains to be established locally is whether the proposed product, follow-up access, financial arrangement and pharmacy process fit together clearly. A detailed plan is valuable documentation, but it should not be mistaken for independent proof of results.

Sources: [3] [1] [2] [10] [4]

Questions & answers

Is the free assessment the same as the $199 visit?

No. Medi-Weightloss describes a free assessment followed by a New Patient Visit. For self-pay patients, that visit costs $199 and includes medical assessment, laboratory work and GLP-1 eligibility review. Confirm what occurs at each stage before booking; the free assessment should not be understood as the entire medical evaluation.

Sources: [10] [12]

Will I definitely receive a GLP-1 prescription?

No prescription is guaranteed. The network says prescription medications require evaluation and approval by a licensed provider, and specific drug availability is confirmed at the New Patient Visit. Its statement that the broader program may help people with BMI of 25 or higher is not sufficient eligibility for a particular medication.

Sources: [11] [6] [10]

Do the $99 and $199 medication offers include membership?

No. The provider explicitly prices medication separately from program fees. Compounded semaglutide starts at $99 for the first month, and compounded tirzepatide starts at $199 for the first month. Subsequent prices, supplied quantities and complete product details are not established in the consulted documentation. Request both the introductory bill and the expected ongoing charges.

Sources: [12]

Can the entire program be completed through telehealth?

The network describes primarily in-person treatment and regular clinic visits. Many locations offer telehealth support between visits, but the documentation does not confirm a fully remote pathway or uniform state-by-state telehealth availability. Ask the specific clinic which appointments require attendance and how remote support works between the scheduled weekly or monthly visits.

Sources: [10] [6]

Can I use HSA or FSA funds?

Medi-Weightloss advertises its programs and medications as HSA/FSA eligible and says many locations accept those accounts. It also instructs patients to confirm eligibility with their plan administrator and says clinics can supply reimbursement documentation. That statement is not an individual tax determination or assurance that every proposed expense will qualify under your account’s rules.

Sources: [12]

Does “not contract-based” mean prepaid money is refundable?

Not necessarily. The provider says ordinary participation does not require advance payment, but some local value or loyalty plans do. The consulted documentation does not clearly explain clinical-program refunds, cancellation notice or unused prepaid balances. Ask for those terms before choosing an optional prepaid arrangement; the absence of a required contract does not establish a refund entitlement.

Sources: [12]

Our assessment

Medi-Weightloss documents a substantive clinic-based offering: initial testing, recurring provider visits, nutrition support, medication monitoring and both branded and compounded prescription options. Its separation of program fees from medication charges and explicit compounded-drug disclosure are useful. The evidence is less complete on recurring prices, exact compounded products, local clinical responsibility, fulfillment and exit terms. Most importantly, the consulted documentation does not establish independently verified outcomes for this network. A reasonable next step is a written local proposal identifying the treating entity, exact medication, dispensing pharmacy, ongoing charges and between-visit support—not an assumption that national service descriptions or medication trial results establish the quality of a particular clinic.

Visit Medi-Weightloss®’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Medi-Weightloss Review: What Its GLP-1 Program Documents—and What It Does Not Prove

At a glance

01A documented clinic network, not a single verified care experience

02What the assessment and first medical visit actually establish

03Follow-up is described more clearly than response times

04Medication names do not settle the product-evidence question

05Named pharmacies improve transparency, but leave delivery unresolved

06Published prices establish entry points, not a complete treatment bill

07Included visits, optional extras and unresolved exit terms

08What research can support—and what remains unmeasured here

Questions & answers

Our assessment

Sources & documentation

Continue reading

A documented clinic network, not a single verified care experience

What the assessment and first medical visit actually establish

Follow-up is described more clearly than response times

Medication names do not settle the product-evidence question

Named pharmacies improve transparency, but leave delivery unresolved

Published prices establish entry points, not a complete treatment bill

Included visits, optional extras and unresolved exit terms

What research can support—and what remains unmeasured here